A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

From mixed to matched: New marker pinpoints therapeutically relevant stem cell-derived islets by The Lundquist Institute edited by Sadie Harley, reviewed by Robert Egan Editors' notes ...

From mixed to matched: new marker pinpoints therapeutically relevant stem cell–derived islets Human pluripotent stem cell–derived islets hold great promise as a functional cure for diabetes.

HOUSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for ...

Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28, 2025HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC ...

Dr. Vera will present Marker's MAR-T cell therapy platform as a novel, non-engineered multi-antigen approach designed to address the shortcomings associated with CAR-T cell therapies. Panelists ...

For their panel, Abou-el-Enein and colleagues selected 36 markers that capture T cell characteristics related to their ability to effectively identify and kill cancer cells.

The analysis of stem cell hierarchies in human cancers has been hampered by the impossibility of identifying or tracking tumor cell populations in an intact environment. To overcome this limitation, ...

Millions of people worldwide are diagnosed and treated for Parkinson’s disease (PD). Unfortunately, in the U.S., there are about 1 million people with PD and 90,000 new cases each year. While the risk ...

HCL cells strongly express all normal B-cell markers, including CD19, CD20 (Figure 1C), CD22, PAX5, and CD79a, but are also characterized by an aberrant immunophenotypic profile, with positivity ...

Their current work focuses on T cells that target metabolite markers that are expressed by a molecule on the cancer cell surface known as major histocompatibility complex-like molecule MRI. These T ...

References 1. Faraz M, Parmigiani A, Monkash N, et al. T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) with negative screening immaturity markers and gamma-delta receptor expression.